Four-in-Five Breakthrough Requests Denied By CBER

Washington Drug Letter
A A
While FDA’s CDER breakthrough therapy designations for new drug products have taken off dramatically, CBER has been a lot more conservative in approving applications for the new designation.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $25.00